Euclidean Capital LLC
In its 13F for Q1 2024 (holdings as of March 31, 2024, filed May 15, 2024), Euclidean Capital LLC reported 12 stock positions worth $780.0 million. Its top holding was SS SPDR S&P 500 ETF Trust-US (SPY) at 65.4% of the portfolio, followed by iShares MSCI India ETF (INDA, 16.0%) and SPDR Gold Shares (GLD, 11.4%). Compared with Q4 2023, it added to 1 and reduced 1. The biggest buy was SS SPDR S&P 500 ETF Trust-US (SPY, shares +6%) and the biggest sale SPDR Gold Shares (GLD, shares −69%).
- Most Recent 13F
- Q2 2026
- Location
- NEW YORK, NY
- CIK
- 0001825034
- Portfolio Value
- $780.0M (Q1 2024)
- SEC Filing
- 0001012975-24-000215 ↗ filed May 15, 2024
Holdings Value
Holdings 12 stocks · $780.0M
| SPY SS SPDR S&P 500 ETF Trust-US | 65.36% | 974,641 | $509.8M | Add +6.3% |
| INDA iShares MSCI India ETF | 16.04% | 2,425,144 | $125.1M | No change |
| GLD SPDR Gold Shares | 11.40% | 432,271 | $88.9M | Reduce -68.9% |
| ORIC Oric Pharmaceuticals Inc. | 1.74% | 989,410 | $13.6M | No change |
| FHTX Foghorn Therapeutics Inc. | 1.35% | 1,573,761 | $10.6M | No change |
| ALEC Alector Inc. | 1.01% | 1,307,858 | $7.9M | No change |
| RAPT THERAPEUTICS INC | 0.76% | 657,899 | $5.9M | No change |
| 23ANDME HOLDING CO | 0.70% | 10,243,122 | $5.4M | No change |
| TNYA Tenaya Therapeutics Inc. | 0.68% | 1,015,705 | $5.3M | No change |
| PMVP PMV Pharmaceuticals Inc. | 0.57% | 2,627,643 | $4.5M | No change |
| NGM NGM Biopharmaceuticals Inc. | 0.20% | 992,168 | $1.6M | No change |
| SRZN Surrozen Inc. | 0.18% | 87,696 | $1.4M | No change |
Other holdings (1): bonds, preferreds, convertibles and warrants · $5K (not counted above)
| Security | Class | Shares / Principal | Value | Change |
|---|---|---|---|---|
| SRZNW Surrozen Inc.-CW25 | *W EXP 08/01/203 | 170,833 | $5K | No change |
Total filed on the 13F, all lines: $780.0M.
Portfolio Sells Q4 2023 → Q1 2024
| GLD SPDR Gold Shares | Reduce -68.9% | 11.40% | −18.50 |
Portfolio Buys Q4 2023 → Q1 2024
| SPY SS SPDR S&P 500 ETF Trust-US | Add +6.3% | 65.36% | +16.30 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 10 | $439.8M | VEU, VTV, INDA, ORIC, TMS |
| Q1 2026 | 9 | $392.3M | VEU, VTV, INDA, ORIC, FHTX |
| Q4 2025 | 11 | $369.4M | VEU, VTV, INDA, FHTX, ORIC |
| Q3 2025 | 10 | $238.0M | VEU, INDA, ORIC, FHTX, ALEC |
| Q2 2025 | 10 | $305.7M | VEU, INDA, ORIC, FHTX, PMVP |
| Q1 2025 | 10 | $266.1M | INDA, VEU, FHTX, ORIC, PMVP |
| Q4 2024 | 10 | $736.7M | SPY, INDA, VEU, ORIC, FHTX |
| Q3 2024 | 11 | $906.8M | SPY, INDA, VEU, FHTX, ORIC |
| Q2 2024 | 10 | $795.8M | SPY, INDA, FHTX, ORIC, ALEC |
| Q1 2024 | 12 | $780.0M | SPY, INDA, GLD, ORIC, FHTX |